Life Edit Therapeutics
Hari Padmanabhan is an accomplished scientist with extensive experience in the field of developmental biology and hit discovery. Currently serving as the Associate Director of Hit Discovery at Life Edit Therapeutics since September 2024, Hari previously held roles at CRISPR Therapeutics from January 2017 to 2023, advancing from Scientist to Principal Scientist. Prior to this, significant research was conducted as a Postdoctoral Fellow at both Harvard University and Massachusetts General Hospital from 2008 to 2016. Hari completed a PhD in Developmental Biology at the Tata Institute of Fundamental Research from 2001 to 2008 and earned an MSc(Hons.) in Biological Sciences from the Birla Institute of Technology and Science, Pilani, from 1996 to 2001.
This person is not in any teams
Life Edit Therapeutics
Life Edit, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the world’s largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The platform allows Life Edit to target any genomic sequence and develop novel human therapeutics for the most challenging genetic diseases by enabling ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene therapies. In addition to developing its own pipeline of cell and gene therapies, Life Edit Therapeutics will continue to strengthen its platform of genome-editing enzymes, provide gene-editing expertise to strategic partners, and form other third-party partnerships to discover and develop new therapies.